59results about "Senses disorder" patented technology

Macrolide compounds, such as the FK506 Substance and its related compounds, are provided for the prevention or treatment of eye diseases, particularly glaucoma. Composition containing such compounds is also disclosed.

The compound represented by formula (I)

(wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing at least one carbon atom and one nitrogen atom and the ringA and ringB share one spiro carbon atom), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof. Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.

This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

A composition for treatment of bacterial infections of the eye is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme. The carrier for delivering at least one lytic enzyme to the eye may be but is not limited to the use of an isotonic solution.

Described herein are compounds useful as agonists of alpha 2B/2C receptors. Pharmaceutical compositions including the presently described compounds and methods of treatment of diseases and conditions with the presently described compounds also are disclosed.

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

A plant extract composition for treating myopia and visual fatigue contains cowberry fruit extract (10-99 wt.%), ginkgo leaf extract (1-90 wt.%) and starch (0-50 wt%). It is prepared through crushingcowberry fruit, boiling in water at 45-80 deg.C for removing pection, adding alcohol, concentrating to obtain its extract, thermal extracting twice of ginkgo leaf, adding alcohol, recovering alcohol solution, concentrating to obtain its extract, then proportionally mixing three of them, and packaging. Its advantages are high effect and high safety.

The invention discloses a series of 8-substitued oxoisoaporphine derivatives as well as a synthetic method and application thereof. The synthetic method comprises the following steps: (1) performing cyclization reaction on 3-chlorophthalic anhydride and phenylethylamine as raw materials twice to construct an 8-Cl-1-azabenzanthrone matrix; (2) ammonifying the 8-Cl-1-azabenzanthrone matrix to obtain 8-amino-7H-dibenzoquinoline-7-ketone; (3) reacting 8-amino-7H-dibenzoquinoline-7-ketone with an acyl chloride compound connected with piperidine to obtain corresponding target products. A study of the applicant discovers that the derivatives have very good inhibition activity on acetylcholin esterase, have relatively good potential medicinal values and are expectedly used for treating Alzheimer diseases, cerebral vascular dementia and related diseases caused by reduction of similar cholinergic neurotransmitters. The structure of the 8-substitued oxoisoaporphine derivatives is shown in a formula.

The invention relates to liquid oxygen in-situ forming gel and a preparation method and application thereof. The liquid oxygen in-situ forming gel comprises the following materials in percentage by weight: 10 to 40 percent of poloxamer, 0.001 to 1 percent of nano silver and 59 to 89.4 percent of solvent. The preparation method comprises the following steps of: adding water into the poloxamer, stirring uniformly, swelling and defoaming to obtain a medicinal base material, adding the nano silver into the base material and stirring uniformly. The liquid oxygen in-situ forming gel can be used for treating vaginitis, rhinitis, otitis and skin tinea diseases. The poloxamer is taken as a temperature sensitive material, and the in-situ forming gel can reside in a human body for more than 20h, so that a medicine taking frequency can be reduced, the compliance of a patient can be improved, a pharmacological treatment effect can be enhanced, and toxic and side effects can be lowered.

The invention provides a pharmaceutical composition for treating diabetic retinopathy. The pharmaceutical composition is a preparation prepared from the following crude medicinal materials by weight: 17-23g of pollen typhae, 3-7g of cinnamon, 7-13 baked ginger, 3-7g of angelica sinensis, 7-13g of motherwort, 7-13g of fructus broussonetiae, 7-13g of thunberg fritillary bulb, 7-13g of cuscuta japonica and 7-13g of turtle shell. The invention also provides a preparation method and use of the pharmaceutical composition. The pharmaceutical composition provided by the invention has a good treatment or disease development inhibition effect on the diabetic retinopathy or diabetic macular edema, the subjective symptoms of a sufferer can be improved, the living quality of the sufferer is improved, and a new choice is provided for clinical medication.

Compounds having a structure of Structure I:

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R¹, R², R³, R⁴, R⁶, Y¹ and Y² are as defined herein, and wherein at least one of R³ or R⁴ is a straight-chain C₁-C₆ haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.

The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index.

The invention provides a composition for eyes and having improved drying protection and retention, and belongs to the field of pharmaceutical preparations. The composition includes cyclosporin, nano micelle in-situ gel, and hyaluronic acid or a pharmaceutically acceptable salt thereof; and the composition is in a liquid form at normal temperature or low temperature, is a hydrosol form when the temperature is more than 35 DEG C, and can still maintain complete under the shear stress caused by the eyelid blinking of patients. A preparation method includes providing first solute and second solute; and mixing the solute under a condition of taking water as a substrate so that the composition including gel dispersoid can be formed. The provided composition is high in bioavailability and small in effect on eye pain and irritation, cannot cause the blurring of vision, can improve the compliance of the patients and/or reduce side-effects, can enhance ocular surface health, and has antibacterial and antiseptic effects; and the preparation method can increase adhesiveness, enhance gelation temperature, prolong retention and effective acting time, rising encapsulation yield, avoid self-agglomeration phenomenon, and enhance antioxidant protection effects and stability performance.

Substituted N—[N-(sulphonylphenyl)sulfonyl-prolyl]-phenylalanine derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells after oral administration and are suitable for once-, twice-, or thrice-a-day oral administration. This invention also relates to compositions containing such compounds and methods of treatment using such compounds.

Described herein is the use of CSF or a CSF-like agent for increasing or promoting glymphatic system clearance in the optic nerve and/or retina for the treatment and/or prevention of retinal diseases, such as age-related macular degeneration, retinal vasculitis and commotio retinae. Also described herein is the use of a therapeutic agent for increasing or promoting glymphatic system clearance in the optic nerve and/or retina for the treatment and/or prevention of retinal diseases. The application further provides adjusted methods for the treatment and/or prevention of glaucoma.

The invention provides a traditional Chinese medicine eye mask capable of relieving eyestrain and black eyes. The traditional Chinese medicine eye mask comprises the following raw medicinal materials in parts by weight: 10-20 parts of centella, 10-20 parts of Angelica sinensis, 10-20 parts of Ligusticum wallichii, 10-20 parts of myrrh, 10-20 parts of radix salviae miltiorrhizae, 10-20 parts of semen cassia, 10-20 parts of pseudo-ginseng, 10-20 parts of concha haliotidis, 10-20 parts of safflower, 10-20 parts of radix paeoniae alba, 10-20 parts of Bletilla striata, 10-20 parts of mint, 10-20 parts of selfheal, 10-20 parts of Chinese violet, 10-20 parts of radix angelicae, 10-20 parts of frankincense, 10-20 parts of Caulis Spatholobi, 10-20 parts of cape jasmine fruit and 10-20 parts of elderberry. According to the theory of traditional Chinese medicine and the modern pharmacological research result, medicinal materials for external application are repeatedly screened to prepare the traditional Chinese medicine eye mask; the traditional Chinese medicine eye mask has the effects of warming and dredging blood vessels, activating skin and removing blood stasis, nourishing blood and removing freckles, removing nebula, subsiding swelling and removing stasis, and moistening skin. The traditional Chinese medicine eye mask can be used for effectively dilating peripheral vessels, improving the face micro-circulation and has a certain improvement effect on periocular hyperpigmentation.

Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents a single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.

The invention discloses a traditional Chinese medicine health-care food for relieving asthenopia. The health-care food is prepared from the following traditional Chinese medicinal materials in parts by weight: 5-30 parts of radix puerariae, 5-30 parts of Chinese wolfberry fruits, 1-10 parts of chrysanthemums and 1-10 parts of mulberries. The radix puerariae and the chrysanthemums are subjected tohigh-temperature puffing pretreatment, and the mulberries and the Chinese wolfberry fruits are subjected to vacuum freeze-drying pretreatment, so that the production efficiency is improved, the content of active ingredients in the produced medicine is higher, the disintegration and dissolution speeds of the medicine are higher, and the curative effect can be better exerted.

Disclosed are a novel hypoxia-inducible factor 1a (HIF-1α) inhibitor, a method of preparing the same, and a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease containing the same as an active ingredient. The compound of Example provided according to an embodiment of the present invention is capable of effectively inhibiting HIF-1α and is thus useful as a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease.

The invention discloses a PEG modified polymyxin or medicinal salt shown in the formula I and a preparation method and application of the PEG modified polymyxin or medicinal salt. The PEG modified polymyxin is a stable compound formed by connecting PEG molecules to polymyxin through covalent bonds. The molecular weight of the PEG modified polymyxin is multiplied, the half-life period is prolonged, and the aims of enhancing the treatment effect and reducing toxicity are achieved. Please see the molecular formula I in the description.

The invention relates to an ophthalmic medicament for treating glaucoma which comprises a clathrate compound prepared by dissolving cilostazol or a salt thereof in a cyclodextrin.

The invention belongs to the technical field of drugs for treating eye diseases, and particularly relates to application of adiponectins (including adiponectin component and mixed liquid component of adiponectin and insulin) in preparing products for improving ocular surface states, treating corneal epithelium and nerve injury and the like. According to the application, as first report, repairing of diabetic corneal epithelium injury and improving of nerve sensitivity can be improved remarkably by partially applying Adiponectin eye drops or Adiponectin/Insulin mixed liquid to in-vivo cornea.